Part B Average Sales Price Drug Rates Finalized; Zoladex Down 12%
Executive Summary
AstraZeneca's prostate cancer therapy Zoladex will be reimbursed at 12% below CMS' previously estimated rate when payment changes for Medicare Part B-covered drugs take effect Jan. 1
You may also be interested in...
Chart: Average Sales Price For Top Medicare Drugs
Average Sales Price For Top Medicare Drugs
Medicare Reimbursement Changes May Impact Hospitals More Than Doctors
Reimbursement changes for hospital outpatient drugs under the Medicare Modernization Act may have an even greater impact on hospitals than the transition to average sales price reimbursement for Part B drugs will have on physicians, Association of Community Cancer Centers Senior Director-Policy & Government Affairs Deborah Walter said
Medicare Reimbursement Changes May Impact Hospitals More Than Doctors
Reimbursement changes for hospital outpatient drugs under the Medicare Modernization Act may have an even greater impact on hospitals than the transition to average sales price reimbursement for Part B drugs will have on physicians, Association of Community Cancer Centers Senior Director-Policy & Government Affairs Deborah Walter said